Prelude Therapeutics Secures FDA Clearance for Cancer Drug Trial

FDA Clearance: The company received FDA clearance for its <strong class="body_output text-content_primary font-semibold" node="[object Object]">Investigational New Drug (IND) application for PRT12396 in the first quarter of 2026.
Clinical Trials: A <strong class="body_output text-content_primary font-semibold" node="[object Object]">Phase 1 study for PRT12396 in patients with polycythemia vera and myelofibrosis is scheduled to begin by the second quarter of 2026.
Financial Stability: Prelude reported <strong class="body_output text-content_primary font-semibold" node="[object Object]">$106 million in cash as of December 31, 2025, providing a cash runway that extends into the second quarter of 2027.

FDA Clears PRT12396, Phase 1 Trial Set for Q2 2026

Prelude Therapeutics announced on March 10, 2026, that it received a critical go-ahead from the U.S. Food and Drug Administration for its new cancer treatment. The company confirmed the FDA cleared its Investigational New Drug (IND) application for PRT12396 during the first quarter of 2026. This clearance is a significant de-risking event, paving the way for a Phase 1 clinical study in patients with polycythemia vera and myelofibrosis, which is slated to begin by the second quarter of 2026. PRT12396 is a mutant-selective JAK2V617F inhibitor, marking a key milestone in Prelude's precision oncology pipeline.

Pipeline Advances With $106M Runway into 2027

Beyond the progress with PRT12396, Prelude outlined a development plan for another key asset, PRT13722, a highly-selective oral KAT6A degrader. The company intends to file an IND for this candidate in mid-2026, with a Phase 1 study anticipated to launch in the second half of the year. These pipeline advancements are supported by a solid financial position. As of December 31, 2025, Prelude held $106 million in cash, cash equivalents, and marketable securities, providing a cash runway expected to last into the second quarter of 2027 and fund its planned clinical initiatives.